Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANRS 109 VISTA: Low-dose Indinavir/Ritonavir + Lamivudine in Multidrug Resistant HIV
NCT00120783Phase 2Terminated
- Sponsor
- ANRS
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indinavir, ritonavir and lamivudine in human immunodeficiency virus infection (HIV), sponsored by ANRS. Primary endpoint: Decrease over 25% in CD4 counts or increase over 0.7 log in plasma HIV RNA at 24 weeks. Started Feb 2002; status: terminated.
02
Drugs
indinavirritonavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00120783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120783.